Alpha Emitter Market Report by Type of Radionuclide (Astatine, Radium, Actinium, Lead, Bismuth, and Others), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Others), End User (Hospitals, Medical Research Institutions, and Others), and Region 2024-2032

Alpha Emitter Market Report by Type of Radionuclide (Astatine, Radium, Actinium, Lead, Bismuth, and Others), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Others), End User (Hospitals, Medical Research Institutions, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A6398
Buy Now

Global Alpha Emitter Market:

The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032. The increasing focus on targeted cancer treatments, along with the rising number of new nuclear-medicine-based product approvals, is bolstering the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 1,476.8 Million
Market Forecast in 2032
US$ 10,975.8 Million
Market Growth Rate (2024-2032) 24.22%


Alpha Emitter Market Analysis:

  • Major Market Drivers: The rising healthcare investments in radiopharmaceuticals, supporting the adoption of alpha emitters in various treatments, are propelling the market.
  • Key Market Trends: The growing demand for innovative cancer therapies to offer new options for difficult-to-treat cancers is acting as a growth-inducing factor.
  • Competitive Landscape: Some of the major market companies include Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions, and RadioMedix Inc., among many others.
  • Geographical Trends: Advanced healthcare infrastructure, high investment in radiopharmaceutical research, and the growing demand for targeted cancer therapies using alpha emitter technologies are augmenting the market in North America.
  • Challenges and Opportunities: The limited production capacity is hindering the market. However, expanding manufacturing infrastructure and fostering partnerships for reliable supply chains will continue to strengthen the market over the forecasted period.
     

Global Alpha Emitter Market


Alpha Emitter Market Trends:

Increasing Demand for Targeted Cancer Therapies

Alpha emitters are gaining prominence due to their ability to precisely target cancer cells, minimizing damage to healthy tissue. Moreover, this demand is driven by the need for more effective treatments, particularly for cancers that resist conventional therapies, thereby offering improved patient outcomes. For instance, in February 2024, the FDA granted a breakthrough device to AlphaMedix, a targeted alpha therapy developed by RadioMedix and Orano Med. This therapy focuses on treating neuroendocrine tumours, showcasing advancements in alpha emitter technologies for more effective and targeted cancer treatments.

Expanding Production Capacity of Alpha Emitters

There is a growing need for larger-scale production as more applications for alpha emitters emerge in cancer treatment. Expanding manufacturing infrastructure is critical to ensure a steady supply of these isotopes, thereby meeting the increasing clinical and research demands. For instance, in January 2024, Orano Med began building a new site in Onnaing, France, dedicated to producing lead-212 radioligand therapies. This facility will enhance large-scale manufacturing capabilities. Therefore, supporting the alpha emitter market outlook.

Advancements in Manufacturing Technology

The development of more efficient and scalable manufacturing technology, such as cyclotron-based production methods, is revolutionizing the alpha emitter industry. These advancements reduce costs, improve isotope purity, and allow for more reliable and widespread availability of alpha particles for medical applications, thereby enhancing the overall market. For instance, in March 2024, Actinium Pharmaceuticals launched a strategic initiative focused on producing Actinium-225 using its proprietary cyclotron-based technology. This development aims to address the growing demand for alpha emitters in targeted cancer therapies, offering a scalable, cost-effective method with high radiochemical purity.

Global Alpha Emitter Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the alpha emitter market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type of radionuclide, medical application, and end user.

Breakup by Type of Radionuclide:

  • Astatine
  • Radium
  • Actinium
  • Lead
  • Bismuth
  • Others
     

Radium currently holds the largest alpha emitter market share

The report has provided a detailed breakup and analysis of the market based on the type of radionuclide. This includes astatine, radium, actinium, lead, bismuth, and others. According to the report, radium represented the largest market segmentation.

Radium, an alpha emitter, is commonly used in treating metastatic bone cancer. Its targeted approach delivers high-energy alpha particles to cancer cells, minimizing damage to healthy tissues. For example, Xofigo is a well-known treatment utilizing radium-223 for effective cancer management.

Breakup by Medical Application:

  • Prostate Cancer
  • Bone Metastasis
  • Ovarian Cancer
  • Pancreatic Cancer
  • Endocrine Tumors
  • Others
     

Ovarian cancer currently holds the largest alpha emitter market demand

The report has provided a detailed breakup and analysis of the market based on the medical application. This includes prostate cancer, bone metastasis, ovarian cancer, pancreatic cancer, endocrine tumors, and others. According to the report, ovarian cancer represented the largest market segmentation.

Ovarian cancer treatments are exploring alpha emitters like Actinium-225 for their precision in targeting cancer cells while sparing healthy tissue. This approach uses alpha particles to destroy cancerous cells. Thus, offering a potentially effective therapy for patients with advanced stages of ovarian cancer.

Breakup by End User:

  • Hospitals
  • Medical Research Institutions
  • Others
     

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, medical research institutions, and others.

According to the alpha emitters forecast report, alpha emitters are used in hospitals, medical research institutions, and beyond for cancer therapies. For example, Thorium-227, which is used in radiopharmaceuticals for targeted treatment of certain cancers, delivers radiation directly to tumors while minimizing harm to healthy tissues.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

North America currently dominates the market

The alpha emitter market outlook report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); ); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share. 

As per the alpha emitter analysis report, North America leads the market due to strong investments in cancer therapies and advanced medical technologies. Apart from this, the region's focus on targeted alpha therapies for cancer treatment drives demand for alpha emitters like Actinium-225. For example, Actinium Pharmaceuticals in the U.S. is developing innovative alpha therapies for difficult-to-treat cancers. Furthermore, strong healthcare infrastructure and increasing research initiatives continue to propel market growth in North America, thereby ensuring the region remains a prominent player in the market.

Competitive Landscape:

The alpha emitter market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Actinium Pharmaceuticals Inc.
  • Alpha Tau Medical Ltd.
  • Bayer AG
  • Fusion Pharmaceuticals
  • IBA RadioPharma Solutions
  • RadioMedix Inc.
     

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

 Alpha Emitter Market Recent Developments:

  • September 2024: Sanofi, RadioMedix, and Orano Med announced a licensing agreement to develop AlphaMedix, a radioligand therapy using lead-212 alpha emitters, which focuses on treating rare neuroendocrine tumors.
  • June 2024: IONETIX produced Actinium-225 for targeted radiotherapies with scalable production planned to meet the needs of cancer treatment.
  • March 2024: Actinium Pharmaceuticals launched a strategic initiative focused on producing Actinium-225 using its proprietary cyclotron-based technology, which offers a scalable, cost-effective method with high radiochemical purity.


Alpha Emitter Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million

Scope of the Report

Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Type of Radionuclide
  • Medical Application
  • End User
  • Region
Type of Radionuclides Covered Astatine, Radium, Actinium, Lead, Bismuth, Others
Medical Applications Covered Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Others
End Users Covered Hospitals, Medical Research Institutions, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions, RadioMedix Inc., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the alpha emitter market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global alpha emitter market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the alpha emitter industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global alpha emitter market was valued at US$ 1,476.8 Million in 2023.

We expect the global alpha emitter market to exhibit a CAGR of 24.22% during 2024-2032.

The rising consumer awareness towards the cell-killing abilities of targeted alpha emitters, along with the increasing number of nuclear medicine-based product approvals, is primarily driving the global alpha emitter market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of various elective cancer treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for alpha emitters.

Based on the type of radionuclide, the global alpha emitter market has been segregated into astatine, radium, actinium, lead, bismuth, and others. Among these, radium currently exhibits a clear dominance in the market.

Based on the medical application, the global alpha emitter market can be bifurcated into prostate cancer, bone metastasis, ovarian cancer, pancreatic cancer, endocrine tumors, and others. Currently, ovarian cancer holds the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global alpha emitter market include Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions, and RadioMedix Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Alpha Emitter Market Report by Type of Radionuclide (Astatine, Radium, Actinium, Lead, Bismuth, and Others), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Others), End User (Hospitals, Medical Research Institutions, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More